KalVista Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States, with headquarters in Cambridge, Massachusetts, United States. The company is focused on developing oral therapies for rare diseases with significant unmet medical needs, with an especially strong emphasis on hereditary angioedema (HAE), a rare genetic disorder that can cause sudden, potentially life-threatening swelling attacks. Founded in 2004, KalVista built its platform around small-molecule drug discovery, particularly plasma kallikrein and factor XIIa inhibition, aiming to offer oral alternatives to injectable acute treatments and burdensome chronic regimens. From an operating perspective, KalVista spent much of its history as a clinical-stage biotech, investing heavily in research, chemistry, and late-stage development before reaching a major commercial inflection point with FDA approval of EKTERLY (sebetralstat). Management describes EKTERLY as the first and only oral on-demand treatment approved in the United States for acute HAE attacks in patients aged 12 years and older. That approval materially strengthens the company’s scientific validation and gives it a clearer commercial pathway in a highly specialized rare-disease market. For investors, the key focus has shifted from clinical promise to execution: market uptake, payer access, physician adoption, and the company’s ability to translate regulatory success into durable revenue growth. KalVista’s pipeline remains relevant beyond its first approved asset. The company continues to develop oral factor XIIa inhibitor programs, which could expand its HAE franchise into prophylaxis and potentially broaden the platform into other indications such as thrombosis and inflammation. This matters strategically because biotech investors often value platform breadth and pipeline optionality as much as the lead product itself. While EKTERLY is the primary value driver today, additional programs could help diversify risk and support longer-term growth if successfully advanced. Geographically, KalVista is anchored in the United States but operates with an international footprint across research, development, regulatory, and commercial activities. That global orientation is important for a rare-disease company, where market expansion beyond the U.S. can significantly extend the opportunity set. Recent milestones have included the 2025 FDA approval of EKTERLY, the rollout of the U.S. launch, and follow-on clinical and conference disclosures supporting the product’s profile. KalVista also announced a transaction involving Chiesi Group, which signals strategic industry interest in the company and its HAE franchise. Overall, KalVista has evolved from a development-stage rare-disease biotech into a more advanced specialty pharmaceutical company with a validated asset, a focused pipeline, and meaningful strategic relevance in the global HAE treatment landscape.